Roche is attempting to convince the EMA’s key advisory panel, the CHMP, that the company’s new multiple sclerosis treatment, Ocrevus (ocrelizumab), should be approved for marketing throughout Europe. This is the second consecutive month that Roche representatives will have appeared in person to answer outstanding concerns the CHMP has with the company’s application for Ocrevus.
Ocrevus is one of just three initial marketing authorizations that the CHMP (the Committee for Medicinal Products for Human Use)...








